Raptor Pharmaceutical Inc.

188 articles about Raptor Pharmaceutical Inc.

• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!

• AltiBio Announces Closing of Series A Preferred Stock Financing Following Positive Proof of Concept Studies

  9/10/2018

  Several of the lead investors in this round were also initial investors in both BioMarin Pharmaceutical and Raptor Pharmaceuticals

• 

  Biotech Movers and Shakers Aug. 27

  8/27/2018

  Who made a splash in the biotech world this week? Here are some notable people.

• Horizon Pharma Completes Acquisition Of Raptor

  10/25/2016

• Another One Bites the Dust... Horizon Pharma Takes Out Bay Area's Raptor in $800 Million Deal

  9/14/2016

• Raptor Presents Results From Meta-Analysis Demonstrating Efficacy Of QUINSAIR Comparable To Other Approved, Inhaled Antibiotics In Cystic Fibrosis Patients

  9/7/2016

• Raptor To Present Data On QUINSAIR And Other Inhaled Antibiotics At The ERS International Congress

  8/24/2016

• Raptor Voted A “Best Places To Work” Company In The North San Francisco Bay Area

  8/19/2016

• Martin Shkreli's Former Firm Retrophin Considering Acquisition of Bay Area's Raptor, Deal Could be Worth $589 Million+

  8/18/2016

• Raptor Reports Second Quarter 2016 Financial Results

  8/5/2016

• Raptor To Hold Second Quarter 2016 Financial Results Conference Call And Webcast On Thursday, August 4, 2016, At 4:30 P.M. EDT

  7/28/2016

• Raptor Reports First Quarter 2016 Financial Results

  5/6/2016

• Three Big Obstacles Bay Area's Raptor Needs to Overcome

  3/22/2016

• Raptor’s PROCYSBI New Drug Submission Accepted By Health Canada With Priority Review

  3/22/2016

• Raptor To Participate In The Cowen and Company 36th Annual Health Care Conference

  3/1/2016

• Raptor To Participate In International Rare Disease Week Through Multiple Patient Advocacy Activities

  2/29/2016

• BioMarin, Raptor, Buck Institute for Age Research Lead Marin Biotech Boom

  12/31/2015

• Raptor Plans To Advance RP103 In A Registration Study In Huntington's Disease Based On Favorable Treatment Effects At 36 Months In CYST-HD Trial

  12/10/2015

• Raptor Release: NIDDK Provides Additional Data From Cynch Study Evaluating RP103 In Pediatric NASH At American Association for Study of Liver Diseases

  11/16/2015

• Raptor To Hold Third Quarter 2015 Financial Results Conference Call And Webcast On Thursday, November 5, 2015, At 4:30 P.M. ET

  10/30/2015